FLT3 and acute myeloid leukemia: Similar to menin inhibitors, SYK inhibitors are being examined in combination with FLT3-ITD inhibitors as well as venetoclax and azacitidine in patients with newly diagnosed AML with NPM1 and FLT3 mutations.